| Literature DB >> 27391898 |
Evgeny A Idelevich1, Karsten Becker1, Janne Schmitz2, Dennis Knaack1, Georg Peters1, Robin Köck1.
Abstract
Results of disk diffusion antimicrobial susceptibility testing depend on individual visual reading of inhibition zone diameters. Therefore, automated reading using camera systems might represent a useful tool for standardization. In this study, the ADAGIO automated system (Bio-Rad) was evaluated for reading disk diffusion tests of fastidious bacteria. 144 clinical isolates (68 β-haemolytic streptococci, 28 Streptococcus pneumoniae, 18 viridans group streptococci, 13 Haemophilus influenzae, 7 Moraxella catarrhalis, and 10 Campylobacter jejuni) were tested on Mueller-Hinton agar supplemented with 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F, Oxoid) according to EUCAST. Plates were read manually with a ruler and automatically using the ADAGIO system. Inhibition zone diameters, indicated by the automated system, were visually controlled and adjusted, if necessary. Among 1548 isolate-antibiotic combinations, comparison of automated vs. manual reading yielded categorical agreement (CA) without visual adjustment of the automatically determined zone diameters in 81.4%. In 20% (309 of 1548) of tests it was deemed necessary to adjust the automatically determined zone diameter after visual control. After adjustment, CA was 94.8%; very major errors (false susceptible interpretation), major errors (false resistant interpretation) and minor errors (false categorization involving intermediate result), calculated according to the ISO 20776-2 guideline, accounted to 13.7% (13 of 95 resistant results), 3.3% (47 of 1424 susceptible results) and 1.4% (21 of 1548 total results), respectively, compared to manual reading. The ADAGIO system allowed for automated reading of disk diffusion testing in fastidious bacteria and, after visual validation of the automated results, yielded good categorical agreement with manual reading.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27391898 PMCID: PMC4938495 DOI: 10.1371/journal.pone.0159183
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Susceptibility of isolates determined by manual reading (standard method) and performance of automated reading of disk diffusion antimicrobial susceptibility testing (with visual adjustment) for fastidious bacteria, compared to manual reading as standard method, n = 144.
| Antimicrobial agent | No. of isolate-antibiotic combinations | No. of resistant isolates | No. of susceptible isolates | No. (%) of very major errors | No. (%) of major errors | No. (%) of minor errors | Categorical agreement, % |
|---|---|---|---|---|---|---|---|
| Penicillin G | 29 | 0 | 29 | ||||
| Levofloxacin | 29 | 0 | 29 | ||||
| Moxifloxacin | 29 | 0 | 29 | ||||
| Norfloxacin | 29 | 0 | 29 | ||||
| Teicoplanin | 29 | 0 | 29 | 1 | |||
| Vancomycin | 29 | 0 | 29 | ||||
| Erythromycin | 29 | 7 | 20 | 2 | |||
| Clindamycin | 29 | 4 | 25 | 1 | |||
| Tetracycline | 29 | 20 | 8 | 1 | |||
| Tigecycline | 29 | 0 | 29 | ||||
| Linezolid | 29 | 0 | 29 | ||||
| Trimethoprim/ sulfamethoxazole | 29 | 0 | 29 | ||||
| Penicillin G | 14 | 0 | 14 | ||||
| Levofloxacin | 14 | 2 | 12 | 1 | |||
| Moxifloxacin | 14 | 0 | 14 | ||||
| Norfloxacin | 14 | 1 | 13 | 1 | |||
| Teicoplanin | 14 | 0 | 14 | ||||
| Vancomycin | 14 | 0 | 14 | ||||
| Erythromycin | 14 | 2 | 12 | ||||
| Clindamycin | 14 | 1 | 13 | ||||
| Tetracycline | 14 | 6 | 6 | 2 | 2 | ||
| Tigecycline | 14 | 0 | 13 | 2 | 1 | ||
| Linezolid | 14 | 0 | 14 | 1 | |||
| Trimethoprim/ sulfamethoxazole | 14 | 0 | 13 | 1 | 1 | ||
| Penicillin G | 25 | 0 | 25 | ||||
| Levofloxacin | 25 | 0 | 25 | ||||
| Moxifloxacin | 25 | 0 | 25 | ||||
| Norfloxacin | 25 | 2 | 23 | 1 | 1 | ||
| Teicoplanin | 25 | 0 | 25 | ||||
| Vancomycin | 25 | 0 | 25 | ||||
| Erythromycin | 25 | 0 | 24 | 1 | |||
| Clindamycin | 25 | 0 | 25 | ||||
| Tetracycline | 25 | 4 | 21 | ||||
| Tigecycline | 25 | 0 | 25 | ||||
| Linezolid | 25 | 0 | 25 | ||||
| Trimethoprim/ sulfamethoxazole | 25 | 0 | 25 | ||||
| Levofloxacin | 28 | 0 | 28 | ||||
| Moxifloxacin | 28 | 0 | 28 | ||||
| Norfloxacin | 28 | 1 | 27 | 1 | |||
| Teicoplanin | 28 | 0 | 28 | 3 | |||
| Vancomycin | 28 | 0 | 28 | 1 | |||
| Erythromycin | 28 | 7 | 21 | 1 | 1 | ||
| Clindamycin | 28 | 5 | 23 | 1 | |||
| Tetracycline | 28 | 5 | 23 | 1 | 1 | ||
| Linezolid | 28 | 0 | 28 | 2 | |||
| Trimethoprim/ sulfamethoxazole | 28 | 4 | 24 | 1 | |||
| Oxacillin | 28 | 7 | 21 | ||||
| Cefaclor | 28 | 0 | 22 | 3 | |||
| Penicillin G | 18 | 0 | 18 | ||||
| Teicoplanin | 18 | 0 | 18 | ||||
| Vancomycin | 18 | 0 | 18 | ||||
| Ampicillin | 18 | 0 | 18 | ||||
| Cefotaxime | 18 | 0 | 18 | ||||
| Cefuroxime iv | 18 | 2 | 16 | ||||
| Cefepime | 18 | 1 | 17 | ||||
| Penicillin G | 13 | 2 | 11 | 2 | |||
| Levofloxacin | 13 | 0 | 13 | 5 | |||
| Erythromycin | 13 | 0 | 0 | 8 | |||
| Tetracycline | 13 | 0 | 13 | ||||
| Trimethoprim/ sulfamethoxazole | 13 | 1 | 11 | 1 | 1 | ||
| Ampicillin | 13 | 1 | 12 | ||||
| Amoxicillin/clavulanic acid | 13 | 1 | 12 | 1 | 1 | ||
| Cefotaxime | 13 | 0 | 13 | 1 | |||
| Cefuroxime iv | 13 | 3 | 10 | 3 | 2 | ||
| Meropenem | 13 | 0 | 13 | ||||
| Ciprofloxacin | 13 | 0 | 13 | 2 | |||
| Nalidixic acid | 13 | 0 | 13 | 7 | |||
| Levofloxacin | 7 | 0 | 7 | ||||
| Moxifloxacin | 7 | 0 | 7 | ||||
| Erythromycin | 7 | 0 | 7 | ||||
| Tetracycline | 7 | 0 | 7 | 1 | |||
| Trimethoprim/ sulfamethoxazole | 7 | 0 | 7 | ||||
| Amoxicillin/clavulanic acid | 7 | 0 | 7 | ||||
| Cefotaxime | 7 | 0 | 7 | 1 | |||
| Cefuroxime iv | 7 | 0 | 7 | ||||
| Meropenem | 7 | 0 | 7 | 3 | |||
| Ciprofloxacin | 7 | 0 | 7 | ||||
| Nalidixic acid | 7 | 1 | 6 | ||||
| Cefixime | 7 | 0 | 6 | 1 | |||
| Erythromycin | 10 | 0 | 10 | 2 | |||
| Tetracycline | 10 | 2 | 8 | 3 | |||
| Ciprofloxacin | 10 | 3 | 7 | ||||
a Number of results within intermediate category can be calculated by subtracting resistant and susceptible results from the number of isolate-antibiotic combinations tested
b Error rates are reported as required by the ISO 20776–2 guideline: VME (%), number of VMEs (i.e. false susceptible results) divided by the number of isolates determined resistant by the standard method; ME (%), number of MEs (i.e. false resistant results) divided by the number of isolates determined susceptible by the standard method); mE (%), number of mEs (i.e. false categorization involving intermediate result) divided by the total number of tested isolates; Categorical agreement (i.e. results within the same interpretative category)
c iv, interpretation according to breakpoints for intravenous use.